Savara (SVRA) Phase 3 Study of Molgradex for Treatment of aPAP Did not Meet its Primary Endpoint

June 12, 2019 4:04 PM EDT Send to a Friend
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced top line data from IMPALA, a pivotal Phase 3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login